Search Results - "Radke, Marc"

Do Higher Wealth Levels Really Guarantee Higher Returns? A Euro Area Test.

Authors: Radke, Marc Peter¹ (AUTHOR)

Source: Intereconomics. Mar2026, Vol. 61 Issue 2, p112-122. 11p.

Dynamic Monitoring of Recurrent Ovarian Cancer Using Serial ctDNA: A Real-World Case Series.

Authors: Rios-Doria, Eric Reichel, Jonathan B. Radke, Marc R. et al.

Source: Current Oncology. Oct2025, Vol. 32 Issue 10, p585. 10p.

This result is not displayed to guests.
Login for full access.

Inflation: Auswirkungen auf die reale Vermögens- und Eigenkapitalrendite.

Authors: Radke, Marc Peter Rupprecht, Manuel

Source: Zeitschrift für das Gesamte Kreditwesen. 6/1/2022, Vol. 75 Issue 11, p38-43. 6p.

Droht das Ende der Rendite? Entwicklung der realen Gesamtvermögensrenditen.

Authors: Radke, Marc Peter Rupprecht, Manuel

Source: Zeitschrift für das Gesamte Kreditwesen. 3/1/2020, Vol. 73 Issue 5, p34-38. 5p.

The Bill, Please! Households' Real Returns on Financial Assets Since the Introduction of the Euro.

Authors: Radke, Marc-Peter Rupprecht, Manuel

Source: Intereconomics. Mar2019, Vol. 54 Issue 2, p106-113. 8p.

Farletuzumab ecteribulin and MORAb‐109, folate receptor alpha and mesothelin targeting antibody–drug conjugates, show activity in poor prognosis gynaecological cancer models.

Authors: Nesic, Ksenija Rybinski, Katherine Ratnayake, Gayanie et al.

Source: Clinical & Translational Medicine. Mar2025, Vol. 15 Issue 3, p1-10. 10p.

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.

Authors: Nesic, Ksenija Krais, John J. Wang, Yifan et al.

Source: Molecular Cancer. 8/5/2024, Vol. 23 Issue 1, p1-10. 10p.

Diagnosis of Ovarian Carcinoma Homologous Recombination DNA Repair Deficiency From Targeted Gene Capture Oncology Assays.

Authors: Krumm, Niklas Khasnavis, Nithisha S. Radke, Marc et al.

Source: JCO Precision Oncology. 5/17/2023, Vol. 7, p1-8. 8p.

Correction: The Bill, Please! Households' Real Returns on Financial Assets Since the Introduction of the Euro.

Authors: Radke, Marc-Peter Rupprecht, Manuel

Source: Intereconomics. May2019, Vol. 54 Issue 3, p194-194. 1p.

Increased TP53 somatic evolution in peritoneal washes of individuals with BRCA1 germline mutations.

Authors: Tee, Xin Ray Hazard, Emma Latorre-Esteves, Elena et al.

Source: Gynecologic Oncology. Nov2024, Vol. 190, p18-27. 10p.

NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.

Authors: Cecchini, Michael Cleary, James M. Shyr, Yu et al.

Source: British Journal of Cancer. Feb2024, Vol. 130 Issue 3, p476-482. 7p.

Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.

Authors: Rodler, Eve Sharma, Priyanka Barlow, William E et al.

Source: Lancet Oncology. Feb2023, Vol. 24 Issue 2, p162-174. 13p.

Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas.

Authors: Somasegar, Sahana Weiss, Arielle S. Norquist, Barbara M. et al.

Source: Gynecologic Oncology. Oct2021, Vol. 163 Issue 1, p130-133. 4p.

Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.

Authors: Ghezelayagh, Talayeh S. Pennington, Kathryn P. Norquist, Barbara M. et al.

Source: Gynecologic Oncology. Mar2021, Vol. 160 Issue 3, p786-792. 7p.

Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years.

Authors: Weiss, Arielle S. Swisher, Elizabeth Pennington, Kathryn P. et al.

Source: Gynecologic Oncology. Oct2020, Vol. 159 Issue 1, p214-220. 7p.

Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma.

Authors: Krimmel-Morrison, Jeffrey D. Ghezelayagh, Talayeh S. Lian, Shenyi et al.

Source: Gynecologic Oncology. Feb2020, Vol. 156 Issue 2, p407-414. 8p.

Constitutional BRCA1 and RAD51C methylation associated with corresponding gene methylation in BRCA wildtype ovarian cancer (156).

Authors: Rodriguez, Isabel Nesic, Ksenjia Liang, Shu Ying et al.

Source: Gynecologic Oncology. 2023 Supplement 1, Vol. 176, pS55-S56. 2p.

Uterine lavage for the detection of ovarian cancer using an expanded gene panel.

Authors: Ghezelayagh, Talayeh Fredrickson, Jeanne Manhardt, Enna et al.

Source: Gynecologic Oncology. Jan2022, Vol. 164 Issue 1, p8-9. 2p.

Evaluation of TP53 mutations in Pap test and blood DNA as novel biomarkers of ovarian cancer risk.

Authors: Ghezelayagh, Talayeh Fredrickson, Jeanne Krimmel-Morrison, Jeffrey et al.

Source: Gynecologic Oncology. 2021 Supplement 1, Vol. 162, pS153-S154. 2p.